Abstract: A system and method may be provided to receive sample RNA reads from patients and generate lists of genes and their associated RNA expression levels in each patient. Some of the RNA reads may be matched to an RNA transcript or gene or gene family in terms of their match likelihood and other RNA reads may be matched to an RNA transcript or gene or gene family through the use of one or more machine learning classifiers. A machine learning classifier may be trained based on the plurality of the lists and a plurality of corresponding patients’ clinical status data to identify gene patterns that recur with a high degree of frequency in the plurality of the lists. Those gene patterns can be capable of modifying a disease or treatment response and can be targeted for drug/treatment development.

Abstract: Methods of detecting, preventing, treating, controlling or managing progressive neurodegenerative diseases are provided. These methods comprise the administration of antibodies that reduce or eliminate monocytes that abnormally express Astrotactin (ASTNI), or block blood monocytes that abnormally express ASTNI from migrating to the central nervous system. Also provided are pharmaceutical compositions that comprise antibodies that specifically target the extracellular domain (ECD2) of ASTNI for the prevention, treatment, control or management of progressive neurodegenerative diseases.

Abstract: A system and method may be provided to receive sample RNA reads from patients and generate lists of genes and their associated RNA expression levels in each patient. Some of the RNA reads may be matched to an RNA transcript or gene or gene family in terms of their match likelihood and other RNA reads may be matched to an RNA transcript or gene or gene family through the use of one or more machine learning classifiers. A machine learning classifier may be trained based on the plurality of the lists and a plurality of corresponding patients' clinical status data to identify gene patterns that recur with a high degree of frequency in the plurality of the lists. Those gene patterns can be capable of modifying a disease or treatment response and can be targeted for drug/treatment development.

Abstract: Methods of detecting, preventing, treating, controlling or managing progressive neurodegenerative diseases are provided. These methods comprise the administration of antibodies that reduce or eliminate monocytes that abnormally express Astrotactin (ASTN1), or block blood monocytes that abnormally express ASTN1 from migrating to the central nervous system. Also provided are pharmaceutical compositions that comprise antibodies that specifically target the extracellular domain (ECD2) of ASTN1 for the prevention, treatment, control or management of progressive neurodegenerative diseases.

Abstract: Methods of treating, controlling or managing diseases associated with uncontrolled inflammatory responses are provided. These methods comprise the administration of small molecule compounds that alter the activity of Tripartite motif containing 8 (TRIM8) in blood monocytes. Also provided are pharmaceutical compositions that comprise small molecule compounds that specifically target the E2-RING domain or the RING-RING dimerization domain of TRIM8 for the treatment, control or management of diseases associated with uncontrolled inflammatory responses.

Abstract: Methods of treating, controlling or managing diseases associated with uncontrolled inflammatory responses are provided. These methods comprise the administration of small molecule compounds that alter the activity of Tripartite motif containing 8 (TRIM8) in blood monocytes. Also provided are pharmaceutical compositions that comprise small molecule compounds that specifically target the E2-RING domain or the RING-RING dimerization domain of TRIM8 for the treatment, control or management of diseases associated with uncontrolled inflammatory responses.

Abstract: Methods of treating, controlling or managing diseases associated with uncontrolled inflammatory responses are provided. These methods comprise the administration of small molecule compounds that alter the activity of Tripartite motif containing 8 (TRIM8) in blood monocytes. Also provided are pharmaceutical compositions that comprise small molecule compounds that specifically target the E2-RING domain or the RING-RING dimerization domain of TRIM8 for the treatment, control or management of diseases associated with uncontrolled inflammatory responses.

Abstract: Methods of detecting, preventing, treating, controlling or managing progressive neurodegenerative diseases are provided. These methods comprise the administration of antibodies that reduce or eliminate monocytes that abnormally express Astrotactin (ASTN1), or block blood monocytes that abnormally express ASTN1 from migrating to the central nervous system. Also provided are pharmaceutical compositions that comprise antibodies that specifically target the extracellular domain (ECD2) of ASTN1 for the prevention, treatment, control or management of progressive neurodegenerative diseases.

Abstract: A system and method may be provided to receive sample RNA reads from patients and generate lists of genes and their associated RNA expression levels in each patient. Some of the RNA reads may be matched to an RNA transcript or gene or gene family in terms of their match likelihood and other RNA reads may be matched to an RNA transcript or gene or gene family through the use of one or more machine learning classifiers. A machine learning classifier may be trained based on the plurality of the lists and a plurality of corresponding patients' clinical status data to identify gene patterns that recur with a high degree of frequency in the plurality of the lists. Those gene patterns can be capable of modifying a disease or treatment response and can be targeted for drug/treatment development.

Abstract: The present invention provides a reactor, which includes: a unitary shell assembly having an inlet and an outlet; a flow path extending within the shell assembly from the inlet to the outlet, the flow path having a steam reformer section with a first catalyst and a water gas shift reactor section with a second catalyst, the steam reformer section being located upstream of the water gas shift reactor section; a heating section within the shell assembly and configured to heat the steam reformer section; and a cooling section within the shell assembly and configured to cool the water gas shift reactor section. The present invention also provides a simplified hydrogen production system, which includes the catalytic steam reforming and subsequent high temperature water gas shift of low-sulfur (<100 ppm by mass) hydrocarbon fuels followed by hydrogen purification through the pressure swing adsorption (PSA).